Treatment of disease with poly-n-acetylglucosamine nanofibers
AssigneeMarine Polymer Technologies, Inc.
InventorsJohn N. Vournakis, Serglo Finkielsztein
Life of this patent
Estimating the term…
Abstract
This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
Claims22
-26. (canceled)
A method for treating atopic dermatitis in a human subject, comprising topically administering a composition comprising shortened poly-β-1→4-N-acetylglucosamine fibers (“sNAG nanofibers”) to the skin of a human subject in need thereof, wherein the sNAG nanofibers comprise 70% or more than 70%, of N-acetylglucosamine monosaccharides, and wherein (i) more than 50% of the sNAG nanofibers are between 1 to 15 m in length, or (ii) the sNAG nanofibers have a molecular weight of 20 kDa to 75 kDa and treatment of a wound with the sNAG nanofibers does not elicit a detectable foreign body reaction 14 days after treatment.
A method for reducing the severity or duration of one or more symptoms associated with atopic dermatitis in a human subject, comprising topically administering a composition comprising shortened poly-β-1→4-N-acetylglucosamine fibers (“sNAG nanofibers”) to the skin of a human subject in need thereof, wherein the sNAG nanofibers comprise 70% or more than 70%, of N-acetylglucosamine monosaccharides, and wherein (i) more than 50% of the sNAG nanofibers are between 1 to 15 μm in length, or (ii) the sNAG nanofibers have a molecular weight of 20 kDa to 75 kDa and treatment of a wound with the sNAG nanofibers does not elicit a detectable foreign body reaction 14 days after treatment.
A method for treating inflammatory bowel disease in a human subject, comprising topically administering a composition comprising shortened poly-β-1→4-N-acetylglucosamine fibers (“sNAG nanofibers”) to the skin of a human subject in need thereof, wherein the sNAG nanofibers comprise 70% or more than 70%, of N-acetylglucosamine monosaccharides, and wherein more than 50% of the sNAG nanofibers are between 1 to 15 m in length.
Dependencies are inferred from the claim text.